Thursday 16 October, 2025
Introduction: Creation of molecules that provide more optimal characteristics for consumers continuously evolves in the drug development industry. Monoclonal antibodies…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
Systematic evaluation of personalized physiologically based pharmacokinetic simulations
Thursday 16 October, 2025
Objectives: Physiologically based pharmacokinetic (PBPK) models typically rely on parameter values that represent the mean of the study cohort or…
Read moreEvaluating the benefit of individual patient data for physiologically based pharmacokinetic (PBPK) simulations
Thursday 16 October, 2025
Objectives: In this work, individualized physiologically-based pharmacokinetic (PBPK) models were built based on information from a clinical study in healthy…
Read moreImpact of Cytochrome P450 2D6, -3A4 and P-glycoprotein on Risperidone’s and 9-Hydroxyrisperidone’s plasma concentrations using a whole-body PBPK approach
Thursday 16 October, 2025
Objectives: The genetic polymorphism of Cytochrome P450 (CYP) 2D6 plays an influential role on the appearance of positive and adverse…
Read moreImpact of OATP1B1 Polymorphism on Pravastatin Pharmacokinetics during Pregnancy; Physiologically Based Pharmacokinetic model Prediction
Thursday 16 October, 2025
Objectives: Pravastatin treatment has been reported to reduce the incidence of pre-eclampsia by 61% and premature birth by 45% [1]. Pravastatin…
Read moreApplication of translational physiologically based pharmacokinetic (PBPK) model for elucidating the complex disposition of ADCs: a case study with T-DM1
Thursday 16 October, 2025
Objectives: Antibody drug conjugates (ADCs) are a class of targeted cancer therapies which aim to widen the therapeutic index by combining…
Read moreA Physiologically Based Pharmacokinetic model to explore the blood-milk barrier in lactating species: case study with oxytetracycline
Thursday 16 October, 2025
Objectives: The presence of antibiotic residues in the milk of farm animals can have an impact on human health, in…
Read moreDevelopment of a joint dissolution and pharmacokinetic model of propafenone and its hydroxylated metabolite
Thursday 16 October, 2025
Introduction: Propafenone (PRO) is a class 1C antiarrhythmic agent, indicated to prolong the time to recurrence of symptomatic atrial fibrillation in…
Read morePBPK Modelling of Atovaquone Long-acting Injectable Formulations
Thursday 16 October, 2025
Background: Malaria remains a global health threat despite the improvement in controlling the spread of this disease. Although effective treatment…
Read moreToxicokinetic modelling of hepatotoxic pyrrolizidine alkaloids: a combined in silico, in vitro and in vivo approach
Thursday 16 October, 2025
Introduction/Objective: Pyrrolizidine alkaloids (PAs) are a class of secondary metabolites in plants of which some are highly hepatotoxic, genotoxic, and…
Read more